Table 3.
Comparison of the LR-M features between intrahepatic cholangiocarcinoma and LR-M hepatocellular carcinoma
| χ2 test |
Rim APHE + late and mild washout |
APHE + early and mild washout |
APHE + late and marked washout |
Rim APHE + early and marked washout |
Rim APHE + early and mild washout |
Rim APHE + late and marked washout |
APHE + early and marked washout |
|||||||
| ICC | LR-M HCC | ICC | LR-M HCC | ICC | LR-M HCC | ICC | LR-M HCC | ICC | LR-M HCC | ICC | LR-M HCC | ICC | LR-M HCC | |
| Positive | 4 | 5 | 42 | 101 | 0 | 0 | 14 | 3 | 30 | 13 | 2 | 0 | 7 | 7 |
| Negative | 95 | 124 | 57 | 28 | 99 | 129 | 8 | 126 | 9 | 116 | 97 | 129 | 92 | 122 |
| Proportion(%) | 4 | 3.9 | 42.4 | 78.3 | 0 | 0 | 14.1 | 2.3 | 30.3 | 10.1 | 2 | 0 | 7.1 | 5.4 |
| P value | > 0.05 | < 0.0001 | - | 0.0018 | 0.0002 | > 0.05 | > 0.05 | |||||||
| 95%CI | -5.6%-6.6% | 22.8%-47.8% | - | 4.3%-20.4% | 9.2%-31.3% | -1.3%-7.1% | -5.2%-9.4% | |||||||
ICC: Intrahepatic cholangiocarcinoma; HCC: Hepatocellular carcinoma; CEUS: Contrast enhanced ultrasound; LI-RADS: Liver imaging reporting and data system. APHE: Arterial phase hyperenhancement; 95% CI: 95% confidence interval.